Peter Bradding
Overview
Explore the profile of Peter Bradding including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
154
Citations
5917
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Bitting K, Hedgespeth B, Ehrhardt-Humbert L, Arthur G, Schubert A, Bradding P, et al.
Allergy
. 2022 Nov;
78(5):1204-1217.
PMID: 36424895
Background: Allergic diseases are triggered by signaling through the high-affinity IgE receptor, FcεRI. In both mast cells (MCs) and basophils, FcεRI is a tetrameric receptor complex comprising a ligand-binding α...
12.
Yang F, Busby J, Heaney L, Pavord I, Brightling C, Borg K, et al.
J Allergy Clin Immunol Pract
. 2022 Jul;
10(11):2925-2934.e12.
PMID: 35863669
Background: Mepolizumab inhibits IL-5 activity and reduces exacerbation frequency and maintenance oral corticosteroid (OCS) dosage in patients with severe eosinophilic asthma (SEA). Some patients remain dependent on OCS despite anti-IL-5...
13.
Diver S, Haldar K, McDowell P, Busby J, Mistry V, Micieli C, et al.
Allergy
. 2022 Jul;
77(11):3362-3376.
PMID: 35778780
Background: In T2-mediated severe asthma, biologic therapies, such as mepolizumab, are increasingly used to control disease. Current biomarkers can indicate adequate suppression of T2 inflammation, but it is unclear whether...
14.
Khalfaoui L, Symon F, Couillard S, Hargadon B, Chaudhuri R, Bicknell S, et al.
Allergy
. 2022 May;
77(10):2974-2986.
PMID: 35579040
Background: The most recognizable phenotype of severe asthma comprises people who are blood eosinophil and FeNO-high, driven by type 2 (T2) cytokine biology, which responds to targeted biological therapies. However,...
15.
McDowell P, Busby J, Hanratty C, Djukanovic R, Woodcock A, Walker S, et al.
Am J Respir Crit Care Med
. 2022 May;
206(5):545-553.
PMID: 35549845
The past 25 years have seen huge progress in understanding of the pathobiology of type-2 (T2) asthma, identification of measurable biomarkers, and the emergence of novel monoclonal antibody treatments. Although...
16.
Alzahrani A, Hakeem J, Biddle M, Alhadian F, Hussain A, Khalfaoui L, et al.
Front Allergy
. 2022 Apr;
2:785100.
PMID: 35387008
The mechanisms underlying corticosteroid insensitivity in severe asthma have not been elucidated although some indirect clinical evidence points toward a role of mast cells. Here, we tested the hypothesis that...
17.
Bradding P
Am J Respir Crit Care Med
. 2021 Dec;
205(4):375-377.
PMID: 34856107
No abstract available.
18.
Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma
Busby J, Matthews J, Chaudhuri R, Pavord I, Hardman T, Arron J, et al.
Eur Respir J
. 2021 Sep;
59(4).
PMID: 34561291
Background: Understanding why patients with severe asthma do not follow healthcare provider (HCP) advice to adjust treatment is critical to achieving personalised disease management. Methods: We reviewed patient choice to...
19.
Murphy A, Boddy C, Bradding P
Breathe (Sheff)
. 2021 Jul;
17(2):210024.
PMID: 34295424
Inhaled corticosteroids (ICS) are the core component of asthma treatment and the only maintenance therapy known to prevent asthma death. There is currently no evidence that biologics prevent asthma death...
20.
Campiani G, Cavella C, Osko J, Brindisi M, Relitti N, Brogi S, et al.
J Med Chem
. 2021 Jul;
64(14):9960-9988.
PMID: 34251197
Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterized by a progressive-fibrosing phenotype. IPF has been associated with aberrant HDAC activities confirmed by our immunohistochemistry studies on HDAC6 overexpression...